Zila Executive and Board Chairman Acquire Stock
July 10 2007 - 4:02PM
PR Newswire (US)
PHOENIX, July 10 /PRNewswire-FirstCall/ -- Zila, Inc.
(NASDAQ:ZILA), announced that the President of its Pharmaceutical
division, Frank Bellizzi, acquired 50,000 shares of Zila common
stock on Friday, July 6. Additionally, Dr. Bellizzi committed 14%
of his salary for the balance of the calendar year to the
acquisition of Zila stock pursuant to the Zila Employee Stock
Purchase Plan. In addition, on Monday, July 9, David R. Bethune,
Chairman of the Board of Zila, acquired 30,000 shares of Zila
common stock. In another development, Dr. David Sidransky tendered
his resignation from the Board, effective August 1, but he will
continue to chair the Zila Medical Advisory Board beyond his
departure from the Board. Chairman Bethune, commented, "Dr.
Sidransky has been a valuable Board member and I am very pleased
that he has agreed to continue to lead Zila's Medical Advisory
Board." About Zila, Inc. Zila, Inc., headquartered in Phoenix, is
an oral cancer screening company focused on the prevention and
treatment of oral disease. Zila is dedicated to establishing
ViziLite(R) Plus as the new standard of care within the medical
community for the early detection of oral abnormalities that could
lead to cancer, with an initial focus on the dental market through
Pro-Dentec(R), a leading designer, manufacturer and marketer of
Soft Tissue Management (STM(R)) products. Sold exclusively and
directly to dental professionals, Pro-Dentec's core products
include the Rota-dent(R) Professional Powered Brush, the
Pro-Select3(R) Piezo-Ultrasonic Scaler System and a suite of
pharmaceutical STM(R) products for both in-office and home-care
use. For more information about Zila, visit http://www.zila.com/.
Safe Harbor Statement This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate, and we disclaim any
obligation to update or revise any such forward-looking statements.
For a more detailed description of these and other cautionary
factors that may affect Zila's future results, please refer to the
documents we file with the Securities and Exchange Commission,
including our Form 10-K for the fiscal year ended July 31, 2006,
our Current Report on Form 8-K filed on December 28, 2006, and our
Form 10-Q for the quarter ended April 30, 2007. DATASOURCE: Zila,
Inc. CONTACT: Lawrence Gyenes, Chief Financial Officer of Zila,
Inc., +1-602-266-6700 Web site: http://www.zila.com/
Copyright
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Oct 2023 to Oct 2024